Webinar
The Fate of FDA Authority: Addressing Recent Supreme Court Decisions on Mifepristone, Chevron, and Beyond
The Fate of FDA Authority: Addressing Recent Supreme Court Decisions on Mifepristone, Chevron, and Beyond
On Thursday, July 11, 2024, Morrison Foerster partner Stacy Amin will moderate a webinar hosted by the Food & Drug Law Institute (FDLI).
The Fate of FDA Authority: Addressing Recent Supreme Court Decisions on Mifepristone, Chevron, and Beyond
July 11, 2024, 2:00–3:30 p.m. ET
This webinar will explore recent Supreme Court decisions impacting FDA’s regulatory authority and the subsequent repercussions for regulated industry. The panel of experts will review the unanimous decision in the case that challenged FDA’s ability to approve the abortion medication mifepristone (FDA v. Alliance for Hippocratic Medicine), as well as the cases that challenged the Chevron doctrine, where courts deferred to an agency’s interpretation of an ambiguous statute (Loper Bright Enterprises v. Raimondo and Relentless, Inc. v. Department of Commerce).
Moderator:
Stacy Amin, Partner, Morrison Foerster
Panelists:
Kalah Auchincloss, Executive Vice President, Regulatory Compliance & Deputy General Counsel, ELIQUENT Life Sciences
Vanessa K. Burrows, Partner, Simpson Thacher & Bartlett LLP
Chad A. Landmon, Partner, Axinn, Veltrop & Harkrider LLP